Quantcast

Latest Menorrhagia Stories

2010-10-06 08:00:00

PARSIPPANY, N.J., Oct. 6 /PRNewswire/ -- Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA(TM) (tranexamic acid) tablets for cyclic heavy menstrual bleeding (HMB) in the October issue of the peer-reviewed journal, Obstetrics & Gynecology. The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB...

2010-09-29 13:53:30

Intrauterine devices, originally developed as contraceptives, can also be used to treat and cure cancer of the endometrium according to new research published online in the cancer journal, Annals of Oncology [1] today (Wednesday 29 September). The finding opens the way for young women with the disease, which affects the lining of the womb, to be treated without the need for a hysterectomy, thus preserving their fertility until they have had all the children they want. Endometrial cancer is...

2010-09-14 08:00:00

PARSIPPANY, N.J., Sept. 14 /PRNewswire/ -- Nearly ninety percent of women who experience heavy periods(1) believe their life during their period would greatly improve if they could reduce their menstrual flow, according to a new Harris Interactive® survey commissioned by Ferring Pharmaceuticals. Living With HMB: A National Survey of 500 Women found that many women experience monthly periods that are so heavy they can sap energy, cause anemia, and in many ways interfere...

2010-08-11 14:03:59

According to a new study published in Pain Primary dysmenorrhea (PDM), or menstrual cramps, is the most common gynecological disorder in women of childbearing age. Lower abdominal pain starts with the onset of menstrual flow and this ongoing pain stimulus can cause alterations throughout the nervous system. In a study scheduled for publication in the September issue of PAIN, researchers report abnormal changes in the structure of the brain in PDM patients, whether or not they are in fact...

2010-07-12 13:00:00

BEDFORD, Mass., July 12 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX) today announced that Glenn Muir, Chief Financial Officer, will present at the Canaccord Genuity 30th Annual Growth Conference 2010 on Wednesday, August 11, 2010 at 1:00 p.m. (Eastern). Interested parties are invited to listen to the live audio webcast of Hologic's investor presentation on the investor section of the company's website at www.hologic.com/investor-overview. An archive of the presentation will be...

2010-06-21 08:00:00

PARSIPPANY, N.J., June 21 /PRNewswire/ -- Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA(TM) (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use. It also...

2010-06-16 05:31:00

ABBOTT PARK, Ill. and SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be...

2010-06-15 13:05:00

WAYNE, N.J., June 15 /PRNewswire/ -- Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi(TM). Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®....

2010-05-24 15:05:00

SAN DIEGO, May 24 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced statistically significant and clinically meaningful top-line efficacy results from its Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. "The Daisy PETAL study was successful, all primary and secondary efficacy endpoints were met, and provided...

2010-05-19 08:00:00

SAN FRANCISCO, May 19 /PRNewswire/ -- Five presentations reporting the results of two placebo-controlled clinical trials evaluating Ferring Pharmaceuticals' LYSTEDA(TM) (tranexamic acid) tablets, a novel, first-in-class, non-hormonal therapy indicated for treatment of women with cyclic heavy menstrual bleeding (HMB), were presented at The American College of Obstetricians and Gynecologists 58th Annual Clinical Meeting in San Francisco, May 15-19, 2010. It is estimated that up to 22...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.